EXACT Sciences Co. (NASDAQ:EXAS) COO Maneesh Arora sold 5,295 shares of EXACT Sciences stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $52.19, for a total transaction of $276,346.05. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Maneesh Arora also recently made the following trade(s):
- On Monday, February 26th, Maneesh Arora sold 12,352 shares of EXACT Sciences stock. The shares were sold at an average price of $42.34, for a total transaction of $522,983.68.
EXACT Sciences Co. (NASDAQ:EXAS) opened at $52.55 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.77 and a current ratio of 7.15. EXACT Sciences Co. has a 12 month low of $19.91 and a 12 month high of $63.60. The firm has a market cap of $6,290.00, a P/E ratio of -25.76 and a beta of 0.71.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Thursday, February 22nd. The medical research company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.09. EXACT Sciences had a negative net margin of 43.01% and a negative return on equity of 24.13%. The business had revenue of $87.41 million during the quarter, compared to analysts’ expectations of $87.42 million. During the same period last year, the company posted ($0.34) EPS. The company’s revenue was up 148.0% on a year-over-year basis. research analysts predict that EXACT Sciences Co. will post -0.84 earnings per share for the current year.
A number of equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, March 1st. Robert W. Baird upgraded shares of EXACT Sciences from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $42.56 to $56.00 in a research report on Tuesday, February 27th. Leerink Swann set a $67.00 price target on shares of EXACT Sciences and gave the company a “buy” rating in a research report on Friday, February 23rd. Benchmark downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Finally, William Blair reiterated a “buy” rating on shares of EXACT Sciences in a research report on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the stock. EXACT Sciences currently has an average rating of “Buy” and an average target price of $52.84.
Several institutional investors and hedge funds have recently modified their holdings of EXAS. C M Bidwell & Associates Ltd. purchased a new position in shares of EXACT Sciences during the 4th quarter worth approximately $117,000. Crow Point Partners LLC purchased a new position in shares of EXACT Sciences during the 4th quarter worth approximately $145,000. Oppenheimer Asset Management Inc. increased its stake in shares of EXACT Sciences by 2,925.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after purchasing an additional 3,072 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of EXACT Sciences by 6,600.0% during the 4th quarter. Advisory Services Network LLC now owns 3,350 shares of the medical research company’s stock worth $176,000 after purchasing an additional 3,300 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of EXACT Sciences during the 3rd quarter worth approximately $183,000. 82.05% of the stock is owned by institutional investors and hedge funds.
WARNING: “EXACT Sciences Co. (EXAS) COO Maneesh Arora Sells 5,295 Shares” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/03/14/exact-sciences-co-exas-coo-maneesh-arora-sells-5295-shares.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.